Loading
institutionsInstitution
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
The Fondazione Pascale in Naples is the national cancer institute for southern Italy; Paolo Ascierto's unit was a lead investigator in the CheckMate and RELATIVITY melanoma trials, and Nicola Normanno's group is a reference for liquid biopsy in lung and colorectal cancer.
Also called: PascaleINT NapoliNational Cancer Institute of Naples
Overview
The Fondazione Pascale is the IRCCS national cancer institute for southern Italy and one of the largest cancer hospitals in the country. Paolo Ascierto's melanoma, immunotherapy and innovative therapies unit has been a leading investigator in the CheckMate and RELATIVITY trials that established checkpoint blockade and the nivolumab-relatlimab combination in melanoma, and the institute hosts the Melanoma Bridge and Immunotherapy Bridge meetings. Nicola Normanno's molecular biology group is a reference for liquid biopsy and predictive biomarkers in lung and colorectal cancer. Clinical programmes span thoracic, gastrointestinal, breast, urological and head and neck oncology, radiotherapy and haematology, with a phase 1 unit and a Campania-wide oncology network role.
Location
Naples, IT
Type
cancer center · Università degli Studi di Napoli Federico II
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#139 · 34 points (0 Newsweek + 0 NCI + 34 from 17 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", including child institutions. 961 works · 15,028 citations · 75% open access · 20% clinical trials · 2% reviews.
Oncology works per year
2142022
2162023
1952024
1972025
1392026
Most works
- Paolo A. Ascierto196 works
- Georgina V. Long85 works
- Sandro Pignata83 works
- Michelino De Laurentiis75 works
- Dirk Schadendorf64 works
- Antonio Avallone62 works
- Piotr Rutkowski55 works
- Jean‐Jacques Grob45 works
- Caroline Robert40 works
- Alessandro Ottaiano38 works
Most cited
- Melanoma immunotherapy trials
- Predictive biomarkers and liquid biopsy
- Thoracic oncology
- Campania oncology network
Maurizio Di Mauro
Direttore Generale (General Director) of Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Healthcare managementHospital administrationInfectious diseases
Physician and hospital manager who is General Director of the Pascale, the national cancer institute in Naples.
Paolo A. Ascierto
Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples
MelanomaImmunotherapyAdjuvant therapy
Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial.
Similar pages
- PersonMichael A. Postow
Shares CheckMate 067, CTLA-4, Ipilimumab, Nivolumab.
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares Relatlimab + nivolumab, CheckMate 067, LAG-3, Bristol Myers Squibb.
- Key paperCheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma
Shares Relatlimab + nivolumab, CheckMate 067, LAG-3, CTLA-4.
- PersonF. Stephen Hodi
Shares CheckMate 067, CTLA-4, Ipilimumab, Nivolumab.
- TrialCheckMate 238
Shares Paolo A. Ascierto, CTLA-4, Ipilimumab, Bristol Myers Squibb.
- PersonHussein A. Tawbi
Shares Relatlimab + nivolumab, LAG-3, Ipilimumab, Nivolumab.
- TrialA Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed
Shares Relatlimab + nivolumab, Bristol Myers Squibb, Nivolumab, Melanoma.
- TrialRELATIVITY-047
Shares Relatlimab + nivolumab, CheckMate 067, LAG-3, Nivolumab.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-CTLA-4)
Ipilimumab · Yervoy
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedFixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)
Relatlimab + nivolumab · Opdualag